In his role as Vice President of In Silico Discovery, Justin oversees a global team delivering cutting-edge solutions in AIML, Bioinformatics, Cheminformatics, Structure-based Drug Design, Protein Modeling, and Generative Design. His modality expertise spans a wide spectrum, including Small Molecule Discovery, Peptides, Antibody Discovery/Engineering, Bispecifics, siRNA, Gene Therapy, Cell Therapy, and RNA platforms and his team impacts programs across all of J&J’s Therapeutic Areas.  Justin holds a PhD in Biophysics and Biochemistry from Washington State University and an NIH Postdoctoral Fellowship at the University of California, San Francisco.  Before becoming head of In Silico Discovery, he held the position of Vice President, Interim Head of Cell Therapy and Vice President, Gene Therapy and Gene Delivery Platforms. Prior to J&J, Justin was Executive Director for Boehringer Ingelheim’s Biotherapeutics Discovery & Engineering team, and earlier, led the discovery of multiple therapeutic molecules at Genentech, including Lunsumio, a bispecific antibody for lymphoma patients.